Bacil Pharma Limited has announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating a significant turnaround in its financial performance. The Board of Directors approved these results during their meeting held on February 13, 2026, at the company's registered office.

Financial Performance Highlights

The company's Q3FY26 results show a remarkable improvement across key financial metrics compared to the same period last year.

Nine-Month Performance Analysis

The nine-month period ended December 31, 2025, also reflected strong performance improvements for the pharmaceutical company.

Revenue and Expense Structure

The company's revenue structure remained consistent with previous periods, with total revenue comprising entirely of other income at ₹6.45 lakhs for Q3FY26. Revenue from operations remained nil during the quarter.

Expense management showed significant improvement:

• Employee benefits expense: ₹0.60 lakhs (Q3FY26) vs ₹3.90 lakhs (Q3FY25)
• Other expenses: ₹1.93 lakhs (Q3FY26) vs ₹2.60 lakhs (Q3FY25)
• Total expenses: ₹2.53 lakhs (Q3FY26) vs ₹6.50 lakhs (Q3FY25)

Other Comprehensive Income

The company reported other comprehensive income of ₹2.18 lakhs in Q3FY26, primarily from gains on fair valuation of financial assets. This contributed to a total comprehensive income of ₹6.10 lakhs for the quarter, compared to a loss of ₹6.20 lakhs in Q3FY25.

Capital Structure

Bacil Pharma's paid-up equity share capital stood at ₹1,397.03 lakhs as of December 31, 2025, with a face value of ₹10 per share. This represents a significant increase from ₹589.00 lakhs in the corresponding period last year.

Auditor's Review

The financial results were reviewed by Sarang Shivajirao Chavan and Associates, Chartered Accountants. The auditors issued a limited review report with several emphasis of matter points, including concerns about fund utilization from preferential allotment and compliance with certain statutory requirements under GST and Income Tax Acts.

Source:

Bacil Pharma has received a regulatory disclosure from Khem-Sum Apparels Overseas Ltd. regarding the complete disposal of its shareholding under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction was completed on December 29, 2025, through an off-market sale.

Transaction Details

Khem-Sum Apparels Overseas Ltd., identified as a promoter group entity, has disposed of its entire holding in Bacil Pharma Limited. The disposal involved 200 equity shares, representing a minimal 0.001% stake in the company's total share capital.

Shareholding Pattern Changes

The disposal has resulted in a complete exit of Khem-Sum Apparels from Bacil Pharma's shareholding structure. The company's stake has been reduced from 0.001% to zero following this transaction.

Company Information

Bacil Pharma Limited's equity shares are listed on the Bombay Stock Exchange. The company maintains a total equity share capital of 14,353,000 equity shares of ₹10.00 each, which remains unchanged following this transaction.

Regulatory Compliance

The disclosure was made in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was signed by Prakash Shah, Director of Khem-Sum Apparels Overseas Ltd. (DIN: 01136800), and submitted on December 30, 2025.

This transaction represents a complete divestment by the promoter group entity from its minimal shareholding in the pharmaceutical company, marking the end of Khem-Sum Apparels' investment in Bacil Pharma Limited.